Singapore markets closed

  • Straits Times Index

    3,269.27
    -32.69 (-0.99%)
     

  • Nikkei

    28,546.98
    +727.65 (+2.62%)
     

  • Hang Seng

    20,175.62
    +93.19 (+0.46%)
     

  • FTSE 100

    7,503.72
    +37.81 (+0.51%)
     

  • BTC-USD

    23,939.88
    -584.53 (-2.38%)
     

  • CMC Crypto 200

    569.30
    -1.99 (-0.35%)
     

  • S&P 500

    4,244.87
    +37.60 (+0.89%)
     

  • Dow

    33,534.27
    +197.60 (+0.59%)
     

  • Nasdaq

    12,942.26
    +162.35 (+1.27%)
     

  • Gold

    1,810.60
    +3.40 (+0.19%)
     

  • Crude Oil

    92.21
    -2.13 (-2.26%)
     

  • 10-Yr Bond

    2.8620
    -0.0260 (-0.90%)
     

  • FTSE Bursa Malaysia

    1,506.19
    +0.63 (+0.04%)
     

  • Jakarta Composite Index

    7,129.28
    -31.11 (-0.43%)
     

  • PSE Index

    6,699.66
    +18.98 (+0.28%)
     
WEALTH:

Chinese solar billionaire doubles fortune despite US sanctions

Global Neuromyelitis Optica (Devic's Syndrome) Clinical Trials Market Research Report, H2 2021 Review - ResearchAndMarkets.com

·3-min read

DUBLIN, December 01, 2021--(BUSINESS WIRE)--The "Neuromyelitis Optica (Devic's Syndrome) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

The clinical trial report provides an overview of Neuromyelitis Optica (Devic's Syndrome) Clinical trials scenario.

This report provides top line data relating to the clinical trials on Neuromyelitis Optica (Devic's Syndrome) . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global clinical trials landscape

  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

  • The Report provides enrollment trends for the past five years

  • Report provides latest news for the past three months

Key Topics Covered:

  • Report Guidance

  • Clinical Trials Report Coverage

  • Clinical Trials by Region

  • Clinical Trials and Average Enrollment by Country

  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific

  • Top Five Countries Contributing to Clinical Trials in Europe

  • Top Countries Contributing to Clinical Trials in North America

  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa

  • Top Five Countries Contributing to Clinical Trials in Central and South America

  • Clinical Trials by G7 Countries: Proportion of Neuromyelitis Optica (Devic's Syndrome) to Central Nervous System Clinical Trials

  • Clinical Trials by Phase in G7 Countries

  • Clinical Trials in G7 Countries by Trial Status

  • Clinical Trials by E7 Countries: Proportion of Neuromyelitis Optica (Devic's Syndrome) to Central Nervous System Clinical Trials

  • Clinical Trials by Phase in E7 Countries

  • Clinical Trials in E7 Countries by Trial Status

  • Clinical Trials by Phase

  • In Progress Trials by Phase

  • Clinical Trials by Trial Status

  • Clinical Trials by End Point Status

  • Subjects Recruited Over a Period of Time

  • Clinical Trials by Sponsor Type

  • Prominent Sponsors

  • Top Companies Participating in Neuromyelitis Optica (Devic's Syndrome) Therapeutics Clinical Trials

  • Prominent Drugs

  • Clinical Trial Profile Snapshots

  • Appendix

Companies Mentioned

  • F. Hoffmann-La Roche Ltd

  • AstraZeneca Plc

  • The Lundbeck Foundation

  • Boston Pharmaceuticals Inc

  • Hbm Holdings Ltd

  • PPD Inc

  • Takeda Pharmaceutical Co Ltd

  • Yantai Rongchang Pharmaceutical Co Ltd

  • Bionure Farma SL

  • Pamplona Capital Management LLP

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/i33f8e

View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005969/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting

Latest stories

  • Stock markets still buoyed by US inflation data

    Stock markets rose on Friday, still riding the positive US inflation data earlier this week as investors mull over the size of the next interest rate move by the US Federal Reserve.

  • Singapore lowers 2022 GDP forecast range to 3-4%

    The current consensus forecast of private sector economists is for a 3.8% growth this year.

  • Keppel, unit to invest in German offshore wind farm in renewables push

    Singaporean conglomerate Keppel Corp said on Friday it would spend 305 million euros ($314.7 million) along with a unit for a 50.01% stake in a special purpose vehicle (SPV) that owns 50% of Borkum Riffgrund 2, an offshore wind farm in Germany. The deal comes as companies race to increase their exposure to renewable energy assets which have risen in prominence in recent years amid a global push towards clean and sustainable energy. "The transaction further accelerates the growth of the group's exposure in renewable energy assets," Keppel said in a statement, adding that it would have a total renewable energy portfolio of about 2.2 gigawatts after the investment was completed.

  • India's domestic airlines get a boost as cap on ticket prices lifts

    Shares of Indian domestic airlines rose on Thursday, a day after the civil aviation ministry said it will remove the restrictions on ticket prices it had imposed two years ago due to the coronavirus pandemic. Domestic airlines IndiGo, SpiceJet Ltd, Air India, Go First and Vistara - a joint venture between the Tata Group and Singapore Airlines - can now price tickets freely. Shares of top airline IndiGo's parent InterGlobe Aviation Ltd rose as much as 2.3% to 2084.6 rupees while smaller rival SpiceJet Ltd jumped as much as 7% to 47.9 rupees.

  • HyD holds "Building and Maintaining Highway Infrastructure through Innovation in Highways Department" exhibition in celebration of HKSAR 25th anniversary

    HONG KONG SAR - Media OutReach - 12 August 2022 - To celebrate the 25th anniversary of the establishment of the Hong Kong Special Administrative Region, the Highways Department (HyD) is holding "Building and Maintaining Highway Infrastructure through Innovation in Highways Department" exhibition from today (August 12) to August 21. Members of the public are invited to visit. "The main theme of the exhibition is 'Road Construction and Maintenance - Unleash The Power of Innovation'. Through real-l

  • Singapore's Olam profit inches up, but higher costs weigh

    Commodity trader Olam Group Ltd on Friday posted a marginal rise in net profit for the first half of fiscal 2022, as a weak performance in the food ingredients unit partially countered strong showing in its Olam Agri business. "The significant demand growth rate and pick-up seen in H2 2021 has slowed down in H1 2022 after the geopolitical crisis, accompanied by the hard pandemic lockdowns in China," Olam said. Olam Agri, which trades grains and animal feed, edible oils, rice, cotton and commodity financial services, still posted a 49.4% jump in its first-half operating profit.

  • Philippine telecom companies feud over ‘fraudulent’ calls

    Philippine telecom giants PLDT Inc. and Globe Telecom Inc. have separately accused new entrant DITO Telecommunity Corp. of “fraudulent” calls made through its network, heightening a public disagreement.

  • Gold inches lower on rate hike expectations by Federal Reserve

    Gold prices edged lower on Thursday, weighed down by prospects of more rate hikes by the U.S. Federal Reserve even as data pointed to signs of inflation peaking. Spot gold fell 0.1% to $1,789.83 per ounce by 1741 GMT. "Gold's been lingering near the key $1,800 level as the market has toned down rate hike expectations, which has also weakened the dollar," although most Federal Reserve commentary continues to hint at more rate increases, said David Meger, director of metals trading at High Ridge Futures.

  • Singapore narrows GDP forecast after economy shrinks in 2Q

    Singapore trimmed its 2022 growth forecast to a range of 3%-4% to reflect an increasingly challenging global environment.

  • Chinese medical portal censored after doubting herbal 'Covid remedy'

    A popular Chinese medical information site has been censored by authorities for "violation of relevant laws and regulations", months after its criticism of a government-backed herbal Covid-19 treatment sent shares in a pharmaceutical giant tumbling.

  • 4 Under-the-Radar Companies with Dividend Yields Exceeding 4%

    Here are four little-known stocks that pay out regular dividends with yields higher than 4%. The post 4 Under-the-Radar Companies with Dividend Yields Exceeding 4% appeared first on The Smart Investor.

  • Sembcorp Marine cuts losses as easing COVID curbs aid project deliveries

    Singapore's Sembcorp Marine Ltd (Sembmarine) said on Friday its half-year loss narrowed 78% from a year earlier, as the oil rig builder finished delayed projects after pandemic curbs were eased while also benefiting from cost management. The company said its overall order visibility has improved on the back of rising oil prices and renewed concerns about energy security amid geopolitical tensions. Sembmarine has been a loss-making business since it posted an annual loss in 2018, in an industry plagued by oil price volatility, a drop in new orders, and the pandemic's impact.

  • NEFIN Group Enters Singapore with A Goal to Invest SGD$100million In Upcoming 5 Years

    Partnering with Tuas Power Supply is the First Step in Materializing the Long-term Commitment into Singapore. There are more strategic partnerships in the pipeline this year.SINGAPORE - Media OutReach - 11 August 2022 - NEFIN Group ("NEFIN"), Asia's leading green independent power producer (IPP), officially launched its brand-new APAC Headquarters in the heart of Singapore's downtown precinct at MacDonald House in Dhoby Ghaut. Highly driven by the entrepreneurial spirit of Singapore, 8 August 20

  • HRnetGroup reports earnings of $34.6 million, to pay interim dividend of 2.13 cents

    Citing its cash balance of $312.7 million, and no bank borrowings, the company says it is shielded from the impact of rate hikes

  • Chinese solar billionaire doubles fortune despite US sanctions

    After the US government barred imports of Hoshine Silicon products, Luo Liguo and his family have only gotten richer — and they’re expanding operations in Xinjiang

  • Singapore trims 2022 growth forecast on strong global headwinds

    Singapore on Thursday narrowed its economic growth forecast this year after the economy contracted in the second quarter compared to the previous three months due to rising inflation and tighter monetary policies, the government said.

  • Singapore narrows 2022 GDP forecast range to 3-4%

    The current consensus forecast of private sector economists is for a 3.8% growth this year.

  • India's July inflation eases to 6.71% as some commodity prices fall

    India's consumer inflation dipped to 6.71% in July, easing for the third month in a row, helped by a slower increase in food and fuel prices and adding to expectations that the central bank may rein in the pace of its policy rate hikes next month. The year-on-year figure, published on Friday by the National Statistics Office, was marginally lower than the 6.78% forecast by economists in a Reuters poll. Economists said they expect the Reserve Bank of India (RBI) to raise its policy rate by at least 25 basis points next month as inflation was likely to remain above its tolerance band through this calendar year.

  • Cellini Redefines Home Aesthetics as it Unveils a New Line of Furniture

    Setting itself up as a leading home-grown designer furniture brand, Cellini sustains its promise to deliver quality craftsmanship, exclusive designs, and timeless furniture pieces. Reimagining the creations of its in-house craftsmen, Cellini's latest launch draws much of its inspiration from the vibrant hues of the colour wheel and the increased demand for exuberant furnishings for revamping one's abode. Putting its signature artistic spin on everyday pieces for the modern individual, this launc

  • Grab's quiet co-founder Tan Hooi Ling: 7 things you may not know

    Though sharing the same surname as Grab CEO Anthony Tan, she's not his sister or spouse. Where did they meet? How did the idea for Grab come about?